Related Experiment Video

Updated: Feb 28, 2026

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

608

Impact of pharmacy services on cystic fibrosis medication adherence

Jeffery T Zobell1,2, Elizabeth Schwab3, Dave S Collingridge4

  • 1Pharmacy, Intermountain Primary Children's Hospital, Salt Lake City, Utah.

Pediatric Pulmonology
|June 14, 2017
PubMed

Insights

Pharmacy services significantly improved medication adherence for pediatric cystic fibrosis (CF) patients. Integrated pharmacy models increased adherence to dornase alfa, reducing hospitalizations.

Area of Science:

  • Pediatric Pulmonology
  • Clinical Pharmacy
  • Health Outcomes Research

Background:

  • Cystic Fibrosis (CF) requires consistent medication adherence for optimal management.
  • Dornase alfa is a key therapy for CF, but adherence can be challenging.
  • The role of integrated pharmacy services in improving pediatric CF care is not fully characterized.

Purpose of the Study:

  • To evaluate the impact of pharmacy services on medication adherence in pediatric CF patients.
  • To assess the effect of pharmacy services on hospitalization rates for CF-related pulmonary exacerbations.
  • To compare adherence rates before and after the implementation of an integrated pharmacy team.

Main Methods:

  • Retrospective analysis of health insurance claims and medical charts (2014-2016).
  • Inclusion of patients from the Pediatric Intermountain CF Center.
  • Measurement of dornase alfa adherence using Medication Possession Ratio (MPR) and review of hospital admissions.

Main Results:

  • Mean yearly dornase alfa MPR increased from 0.75 in 2014 to 0.92 in 2016.
  • Patients were 2.8 times more likely to be adherent with an integrated pharmacy team (P < 0.001).
  • Patients were 2.4 times more likely to be adherent with a dedicated CF clinic pharmacist (P = 0.001).

Conclusions:

  • Pharmacy services demonstrably improve dornase alfa adherence in pediatric CF patients.
  • Integrated and dedicated CF clinic pharmacy models enhance medication adherence.
  • These findings support the integration of pharmacy services in CF care to improve patient outcomes.
Abstract

Keywords:
clinical pharmacydornase alfamedication possession ratio

More Related Videos

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis07:16

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis

Published on: September 20, 2024

1.9K
Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

1.2K

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
588
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
953
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
331
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
302
Factors Influencing Drug Absorption: Disease States and Pharmacology01:25

Factors Influencing Drug Absorption: Disease States and Pharmacology

Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
1.6K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
316